| Followers | 25 |
| Posts | 2781 |
| Boards Moderated | 0 |
| Alias Born | 03/18/2013 |
Saturday, November 30, 2024 1:13:19 PM
(OT) I know, another stock recommendation..... I bought into Lumen years ago ($10) when it was paying a 10% dividend. I know, highly leveraged debt, stopped paying the dividend, stock cratered, Low of Year .78, High of Year 10.29. Great trading stock if you can time it right. Let me ask all of you this question; It's great to own Artificial Intelligent stocks like Palantir, Nvidia, IONQ, etc. But think for a moment how these companies will interface (transport their data) with each other? My money's on transporting the data. The buildout of Data Centers, the supply of Electricity to support these data centers?
I've been recommending the following Three (3) Sectors to anyone that I meet.
AI related (LUMN, PLTR, etc.)
Electric Vehicles (LUCID, RIVN, TSLA (too expensive)
Electric Utilities (They pay dividends)
It's healthy to have discussions on up and coming technologies. I'm still heavily into Amarin too, I just think Alex Denner is not quite done, there is a plan, we're just not privvy to it.
BTW, Posting on Yahoo is a joke. I'm glad JesseLivermore suggested moving the Amarin discussion to IHUB years ago. Yahoo is so greedy that they allow Spammers to post their nonsense. It detracts from legitimate posters. Yahoo used to be a good place to get information. They also have their Network Nazi's who vehemently reject any form of Freedom of Speech.
I've been recommending the following Three (3) Sectors to anyone that I meet.
AI related (LUMN, PLTR, etc.)
Electric Vehicles (LUCID, RIVN, TSLA (too expensive)
Electric Utilities (They pay dividends)
It's healthy to have discussions on up and coming technologies. I'm still heavily into Amarin too, I just think Alex Denner is not quite done, there is a plan, we're just not privvy to it.
BTW, Posting on Yahoo is a joke. I'm glad JesseLivermore suggested moving the Amarin discussion to IHUB years ago. Yahoo is so greedy that they allow Spammers to post their nonsense. It detracts from legitimate posters. Yahoo used to be a good place to get information. They also have their Network Nazi's who vehemently reject any form of Freedom of Speech.
Recent AMRN News
- Earnings Report Shows Narrowing Losses as Amarin (AMRN) Advances Partner-Led Growth Strategy • IH Market News • 04/29/2026 02:19:17 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/29/2026 11:06:34 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/29/2026 11:05:15 AM
- Amarin Reports 2026 First Quarter Financial Results • GlobeNewswire Inc. • 04/29/2026 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/22/2026 09:00:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:02 PM
- Amarin to Report First Quarter 2026 Financial Results and Host Conference Call on April 29, 2026 • GlobeNewswire Inc. • 04/15/2026 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/10/2026 09:01:34 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/10/2026 09:00:20 PM
- American College of Cardiology (ACC) Scientific Sessions 2026 Underscore the Need for Complementary Therapies Including Icosapent Ethyl (IPE) in Treatment of Elevated Triglycerides and Cardiovascular Risk Reduction • GlobeNewswire Inc. • 04/08/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:30:11 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/30/2026 09:57:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/27/2026 09:00:07 PM
- Amarin Highlights Guideline Recommended Role of Icosapent Ethyl in Managing Cardiovascular Risk Following Release of Updated 2026 ACC/AHA/Multisociety Dyslipidemia Guideline • GlobeNewswire Inc. • 03/18/2026 12:30:00 PM
- New REDUCE-IT Data in Patients at Extreme Cardiovascular Risk and In Vitro Research on the Mechanistic Effects of Eicosapentaenoic Acid (EPA) on Lipoprotein(a) [Lp(a)] Oxidation to be Presented at the American College of Cardiology’s (ACC) Annual Scienti • GlobeNewswire Inc. • 03/16/2026 12:15:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/02/2026 10:31:01 PM
- Effects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT® Post Hoc Analysis Published in the European Journal of Preventive Cardiology • GlobeNewswire Inc. • 03/02/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 12:05:26 PM
- Amarin Reports Fourth Quarter and Full Year 2025 Financial Results • GlobeNewswire Inc. • 02/25/2026 12:00:00 PM
- This American Heart Month Amarin Spotlights the Need to Prioritize Proven Widely Available Yet Underutilized Therapies in the Battle Against Cardiovascular Disease • GlobeNewswire Inc. • 02/23/2026 01:00:00 PM
